Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Date:2/20/2008

$440 million. Amortization expense for 2008 is expected to be approximately $80 million.

In 2008, the Company expects to incur pre-tax costs associated with the planned closure of its Carmel, NY manufacturing facilities of approximately $34 million which includes accelerated depreciation, severance, retention and other related plant closure costs. The Company also expects to incur $8 million of licensing and debt repurchase charges. These charges are excluded from Watson's 2008 adjusted earnings per diluted share forecast as detailed in Table 6 below.

For 2008, the Company expects GAAP earnings per diluted share to be between $1.68 to $1.78 and adjusted earnings per diluted share to be between $1.90 and $2.00. Excluding special items as detailed in the EBITDA reconciliation table below, adjusted EBITDA is expected to be between $555 and $575 million.

Webcast and Conference Call Details

Watson will host a conference call and webcast today at 8:30 a.m. Eastern Standard Time to discuss fourth quarter and full year 2007 results, projections for 2008 and recent corporate developments. The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573. A taped replay of the call will be available by calling (800) 642-1687 with access pass code 32008884. The replay may be accessed from international locations by dialing (706) 645-9291 and using the same pass code. This replay will remain in effect until midnight Eastern Standard Time, February 29, 2008. To access the live webcast, go to Watson's Investor Relations website at http://ir.watson.com.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal p
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
(Date:12/19/2014)... 2014  Decision Resources Group finds that the ... grow moderately through 2023 as the aging population, increasing ... dental biomaterials all spur procedure volumes. Growth will be ... China and India , ... reach for a larger proportion of the population. ...
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... PALO ALTO, Calif. , May 4 "BIO has ... of the biotechnology sector.  It is my goal to build upon these ... fosters the right policy environment for the biobased solutions that our industry ... , , ...
... slips into the sole of your sneaker, but it,s a ... hundreds of times faster ― a communications technology "enabler" that ... the future, currently being created by Dr. Koby Scheuer of ... Scheuer has developed a new plastic-based technology for the nano-photonics ...
... BERLIN and CHICAGO , May ... the most important biotechnology segments in Germany .,With an ... German diagnostics,market, the segment enjoys a compound annual growth ... trends toward personalized,medicine that are correspondingly increasing the market for ...
Cached Biology Technology:Statement from Genencor CEO Tjerk de Ruiter Upon Being Elected as Chair of the Industrial & Environmental Section and Board of Directors of the Biotechnology Industry Association (BIO) 2An optical traffic cop for rapid communication 2BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth 2BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth 3
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... HOUSTON (Jan. 31, 2012) Just the mention ... are often painful and sometimes difficult to remove, and 10 ... the risk of developing kidney stones is exacerbated due to ... that resource limitations and distance from Earth could restrict treatment ...
... Over the past 30 years, numerous studies have linked ... bipolar disorder, schizophrenia, anxiety disorder and dementia. Genetic fragments ... disorders in a range of mammals and birds, have ... study results have been inconsistent. Now, the first ...
... who have Ulcerative Colitis (UC) or Ileal Pouch know ... between flares is crucial to successfully living with the ... drugs, dietary changes and, for many, the addition of ... management of these conditions. Now, Sigma-Tau Pharmaceuticals, Inc., maker ...
Cached Biology News:Twinkle, twinkle kidney stone: With a push you could be gone 2Twinkle, twinkle kidney stone: With a push you could be gone 3Does Borna disease virus cause mental illness? 2Maker of VSL#3 probiotic offers assistance program for ulcerative colitis and ileal pouch patients 2
... Intended for users requiring mass ... AXIMA-LNR linear MALDI TOF Mass spectrometer ... QA/QC applications and for high performance ... oligonucleotide QA/QC, SNP analysis, protein detection, ...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
... DNA is an ideal small concentrator for ... capable of removing water and organic solvents ... tubes, microplates, vials and round bottom flasks. ... the busy lab. ,The built-in special runs ...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
Biology Products: